(Q82989069)

English

Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer

scientific article published on 01 May 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568471%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568471%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

phase I clinical trial

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

object named as

George Wilding

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568471%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Patrick Soulie

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568471%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Donald Trump

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568471%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Ashis Das-Gupta

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568471%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Eric Small

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568471%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

1 May 2006

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568471%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568471%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

106

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568471%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568471%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1917-1924

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568471%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21831

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate cancer: horizons in the development of novel anti-cancer strategies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21831

7 January 2021

based on heuristic

inferred from DOI database lookup

State-of-the-art treatment of metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21831

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21831

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21831

7 January 2021

based on heuristic

inferred from DOI database lookup

Growth factors and their receptors: new targets for prostate cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21831

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21831

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21831

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21831

7 January 2021

based on heuristic

inferred from DOI database lookup

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21831

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21831

7 January 2021

based on heuristic

inferred from DOI database lookup

The McGill Pain Questionnaire: Major properties and scoring methods

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21831

7 January 2021

based on heuristic

inferred from DOI database lookup

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21831

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21831

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21831

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics and pharmacodynamics of estramustine phosphate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21831

7 January 2021

based on heuristic

inferred from DOI database lookup

Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21831

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21831

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21831

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568471%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16568471%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q82989069&oldid=1751089530"